Sarbajit Mukherjee

Systemic therapies for gastroenteropancreatic neuroendocrine carcinomas: Current paradigm and future avenues

Charles W Shi, Aagamjit Singh, Atulya A. Khosla, Rohit Thummalapalli et autres

us (code pays fourni par la source)

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline, Version 2026.1.2

Manish A. Shah, Jacob S. Marzalik, Erin B. Kennedy, Dana C. Deighton et autres

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in …

us, jp (code pays fourni par la source)

Circulating tumor DNA in gastrointestinal cancers: promise, pitfalls, and the path forward

Sarbajit Mukherjee, Azza Sarfraz, Kyaw Lin Aung, Manmeet Singh Ahluwalia

Circulating tumor DNA (ctDNA) has emerged as a powerful prognostic biomarker in gastrointestinal (GI) oncology, with the strongest evidence in colorectal cancer. Postoperative ctDNA positivity identifies patients at high risk of recurrence, and serial clearance patterns further refine risk. However, prognostic validity …

us (code pays fourni par la source)

Phase II study of avelumab and trastuzumab with FOLFOX chemotherapy in previously untreated HER2-amplified metastatic gastroesophageal adenocarcinoma

Ashwin Somasundaram, Sarbajit Mukherjee, Mehmet Akce, Joseph Chao et autres

Background: Trastuzumab and multiagent chemotherapy have been the standard of care for the 20-30% of metastatic gastric and esophageal adenocarcinomas that overexpress HER2. Preclinical data show that trastuzumab requires a functional adaptive immune system for efficacy, suggesting synergy of trastuzumab combined with …

us (code pays fourni par la source)

Split immunomodulatory impact of leptin on human myeloid cells: key role of IDO1 in counteracting the immunostimulatory effect of leptin

Bowen Dong, Spencer Rosario, Wei Luo, Adam Brinkman et autres

Obesity increases cancer incidence and aggressiveness but is paradoxically associated with improved response to immunotherapy. Here, we show that intratumoral levels of leptin (LEP), a factor contributing to the development of obesity, predict improved outcomes of breast and liver cancers. In contrast, …

us (code pays fourni par la source)

Safety of immune checkpoint modulators beyond PD-1/PD-L1 and CTLA-4 in solid tumors: a meta-analysis

Yu Fujiwara, Yui Okamura, Mrinalini Ramesh, Yasmin Fakhari Tehrani et autres

BACKGROUND: Novel agents targeting immune checkpoints are under development to overcome resistance to PD-1/PD-L1 and CTLA-4 blockade. Incidences of immune-related adverse events (irAEs) and toxicity profiles of novel agents remain unelucidated. METHODS: We searched PubMed/MEDLINE, Embase, and Web of Science for clinical …

us, jp (code pays fourni par la source)

Understanding the Promise and Challenges of Tumor-Agnostic Therapy: Could One Size Really Fit All?

Yin M. Myat, Kyaw Z. Thein, Myat M. Han, Manmeet Singh Ahluwalia et autres

Tumor-agnostic therapies represent an evolving approach in oncology, shifting from conventional histology-based treatment models to strategies guided by molecular alterations. Regulatory approvals of therapies targeting tumors harboring genomic alterations such as NTRK and RET fusions, BRAF V600E mutation, and those with deficient …

us (code pays fourni par la source)

Abstract 5348: Tumor remodeling pathways are enriched in the tumor microenvironment of obesity-associated colorectal cancer.

Yu Fujiwara, Sarbajit Mukherjee, Yali Zhang, Jianmin Wang et autres

Abstract Background: Obesity is a known risk factor for colorectal cancer (CRC) that promotes systemic inflammation and T-cell dysfunction, yet the characteristics of the tumor immune microenvironment (TIME) in obesity-associated CRC are not well-defined. Therefore, we performed a comprehensive analysis to characterize …

us (code pays fourni par la source)

CLO26-074: A Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients with Metastatic Neuroendocrine Tumors (NETs)

Reem Dergham, Michael J. Ciesielski, Han Yu, Sheila A. Figel et autres

us (code pays fourni par la source)

TP53 mutation is associated with improved disease control in patients with advanced RAS wild‐type colorectal adenocarcinoma treated with cetuximab and pembrolizumab

Christos K Fountzilas, Spencer R. Rosario, Agnieszka K. Witkiewicz, Henry G. Withers et autres

Abstract Immunotherapy with checkpoint inhibitors targeting the PD1/PD‐L1 and CTLA4 pathways has limited activity in patients with microsatellite stable (MSS) colorectal adenocarcinoma (CRC). In a prior study, the combination of cetuximab and pembrolizumab failed to improve outcomes for patients with advanced RAS …

us (code pays fourni par la source)

ISDE guidelines on the management of cT2N0 esophageal cancer

Geoffrey Paul Kohn, Virginia Litle, Yousif Eliya, Samantha Leng et autres

Esophageal cancer incidence is rising globally, with at least 500,000 new cases diagnosed annually. Management options for non-metastatic disease include primary resection, neoadjuvant or perioperative therapies, or definitive non-surgical treatment, with the choice being guided by tumor staging, histology, patient fitness, and …

au, us, no, gb, nl, hr (code pays fourni par la source)

NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal

Van K. Morris, Kristen Keon Ciombor, Lianchun Xiao, Joshua Kapere Ochieng et autres

PURPOSE In the previously completed NCI9673 (part A) single-arm study, the antiprogrammed death (PD)–ligand-1 antibody nivolumab demonstrated efficacy for patients with metastatic anal cancer. In NCI9673 (Part B), we evaluated the anticytotoxic T-cell lymphocyte antigen-4 (CTLA-4) antibody ipilimumab in combination with nivolumab …

us (code pays fourni par la source)